Market closed
Tiziana Life Sciences Ltd./$TLSA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
Ticker
$TLSA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
9
Website
TLSA Metrics
BasicAdvanced
$111M
-
-$0.13
0.15
-
Price and volume
Market cap
$111M
Beta
0.15
52-week high
$1.91
52-week low
$0.92
Financial strength
Current ratio
0.854
Quick ratio
0.815
Long term debt to equity
1.995
Total debt to equity
9.65
Interest coverage (TTM)
-3,159.80%
Management effectiveness
Return on assets (TTM)
-69.58%
Return on equity (TTM)
-181.23%
Valuation
Price to book
56.34
Price to tangible book (TTM)
56.34
Price to free cash flow (TTM)
-26.771
Growth
Earnings per share change (TTM)
-29.05%
3-year earnings per share growth (CAGR)
-38.82%
TLSA News
AllArticlesVideos
Tiziana Life Sciences begins patient dosing in Phase 2 MS trial at Johns Hopkins
Proactive Investors·3 days ago
Tiziana Life Sciences Announces Johns Hopkins University Commences Dosing Nasal Foralumab in Phase 2 Multiple Sclerosis Clinical Trial
GlobeNewsWire·3 days ago
Tiziana Life Sciences begins dosing in Phase 2 trial for intranasal foralumab in SPMS
Proactive Investors·2 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Tiziana Life Sciences Ltd. stock?
Tiziana Life Sciences Ltd. (TLSA) has a market cap of $111M as of April 05, 2025.
What is the P/E ratio for Tiziana Life Sciences Ltd. stock?
The price to earnings (P/E) ratio for Tiziana Life Sciences Ltd. (TLSA) stock is 0 as of April 05, 2025.
Does Tiziana Life Sciences Ltd. stock pay dividends?
No, Tiziana Life Sciences Ltd. (TLSA) stock does not pay dividends to its shareholders as of April 05, 2025.
When is the next Tiziana Life Sciences Ltd. dividend payment date?
Tiziana Life Sciences Ltd. (TLSA) stock does not pay dividends to its shareholders.
What is the beta indicator for Tiziana Life Sciences Ltd.?
Tiziana Life Sciences Ltd. (TLSA) has a beta rating of 0.15. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.